Long non-coding RNA expression profile in human gastric cancer and its clinical significances
BACKGROUND:Long non-coding RNAs are prevalently transcribed in the genome yet their potential roles in human cancers are not well understood.
Trending on the Topix Network
Fri Mar 14, 2014
Alarming increase in Hep C deaths among baby boomers
ELIZABETH JACKSON: Australians who contracted hepatitis C decades ago are only now starting to develop terminal liver disease at an alarming rate.
Free Hepatitis C screening and walk at Lake Merritt
Just days into his second round of treatment for Hepatitis C, James Jensen spent his afternoon painting banners, making buttons and assembling information packets to educate people about the chronic liver disease which affects an estimated 3.2 million people in the United States.
Presentation at Annual Society of Surgical Oncology Meeting Updates...
The oral presentation was given at the 67th Society of Surgical Oncology Annual Cancer Symposium being held March 12-15, 2014 at the Phoenix Convention Center in Phoenix, Arizona.
Thu Mar 13, 2014
Liver Cancer: A Matter of Facts
About 75,000 men and women will face a diagnosis of liver cancer in the United States this year.
Gene variants protect against relapse after treatment for hepatitis C
More than 100 million humans around the world are infected with hepatitis C virus.
Wed Mar 12, 2014
Delcath Reports 2013 Fourth Quarter And Full Year Results
NEW YORK, March 12, 2014 /PRNewswire/ -- Delcath Systems, Inc. today reported financial results and operational developments for the fiscal fourth quarter and full year ended December 31, 2013.
Tue Mar 11, 2014
BRIEF: Can-Fite Biopharma raises $5m
Can-Fite issued 982,344 American Depositary Shares at per ADS. Can-Fite said that it held the placement following the success of its multicenter clinical trials of its treatments for rheumatoid arthritis and psoriasis.
Sorafenib (Nexavar) Fails Phase III Trial in Patients With Liver Cancer
A phase III study evaluating the investigational use of sorafenib as an adjuvant treatment for patients with hepatocellular carcinoma who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.
The Motley Fool
Today's Top Biotech Stories: Myriad Genetics, Bayer, Amgen, and Synta
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of...
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc., an Amgen subsidiary , today announced that a Phase 3 trial evaluating the investigational use of NEXAVARA tablets as an adjuvant treatment for patients with hepatocellular carcinoma , or liver cancer, who had no detectable disease after surgical resection or local ablation, did not ... (more)
UPDATE 1-Bayer's Nexavar misses target in liver cancer trial
Germany's Bayer said a final stage Phase III clinical trial of cancer drug Nexavar as an adjuvant therapy for liver cancer did not meet its main target.
Mon Mar 10, 2014
St. Luke's Participates in Interventional Clinical Trial to...
St. Luke's University Health Network is one of three sites nationwide chosen to enroll patients in a new study using the therapeutic agent PV-10 for late-stage liver cancer.
The Badger Herald Online
UW hosts sixth annual dance marathon
Featuring Dean of Students Lori Berquam's hot pink hair, the sixth annual madiTHON brought students and campus community members together to "dance because they can and stand for those who can't" Saturday at Memorial Union.
Sun Mar 09, 2014
Family, friends, strangers gather to say good-bye to baby Luke
Springfield-Several hundred people gathered at Kiley Middle School Sunday in memory of Luke DeMarco, a 17-month-old boy who died of liver cancer.
Inter Press Service
A Matter of Life and Death
Martin Khor, executive director of the South Centre, warns that negotiations on the Trans Pacific Partnership Agreement are a matter of life and death.
Press and Journal News
Baltacha pledge in liver cancer struggle
The 30-year-old, who retired from the sport last November due to a series of injuries, is undergoing treatment and thanked people for their support.
Sat Mar 08, 2014
Tennis Star Elena Baltacha Battling Liver Cancer
The former U.K. number one, who retired from the sport last year , confirmed her health battle in a statement and vowed to fight the disease.
Fri Mar 07, 2014
Catholic World News
Cardinal George reveals cancer is advancing
Chicago's Cardinal Francis George has disclosed that a cancer in his kidney is showing "signs of new activity," and will require more aggressive treatment.
Elena Baltacha Diagnosed with Liver Cancer
It's been revealed that former British number one tennis player Elena Baltacha has been diagnosed with cancer of the liver.